<DOC>
	<DOC>NCT02810743</DOC>
	<brief_summary>Investigator-initiated, international, multicentre, randomized, open-label, (neo)adjuvant phase III study in target population (stage III, HER2-negative, BRCA1-like breast cancer patients) comparing optimized standard-dose chemotherapy with intensified, alkylating chemotherapy with stem cell rescue.</brief_summary>
	<brief_title>Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<criteria>Women and men with stage III adenocarcinoma of the breast harboring signs of a breast cancer with features of homologous recombination deficiency (HRD) Age of 1865 years The tumor must be HER2negative Treatment must start within 8 weeks after the last surgical resection Eastern Cooperative Oncology Group (ECOG) performance status 01 Previous radiation therapy Previous chemotherapy Any previous treatment with a PARPinhibitor, including olaparib Preexisting neuropathy from any cause in excess of Grade 1 Chronic concomitant use of known strong or moderate CYP3A inducers</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>